University of Washington: Carcinoma, Ovarian Epithelial trials

The registry lists 13 Carcinoma, Ovarian Epithelial studies with University of Washington as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 6Phase 2 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsTerminatedNCT03641287Not applicableResults posted
• Lavage of the Uterine Cavity for Diagnosis of Ovarian CancerTerminatedNCT03606486Not applicableResults posted
• IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing SurgeryTerminatedNCT03029611Phase 2Results posted
• Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous ChemotherapyCompletedNCT00466960Phase 2Results posted
• Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving TrastuzumabCompletedNCT00194714Phase 1/2Results posted
• Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype FamiliesCompletedNCT03119285
• Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse CaregiversCompletedNCT02401321Not applicable
• Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive StudyCompletedNCT01544049
• Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian CancerCompletedNCT01322802Phase 1
• Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerCompletedNCT01104259Phase 1
• Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian CancerCompletedNCT00436254Phase 1
• Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerCompletedNCT00357448Phase 1
• Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu VaccineCompletedNCT00228358Phase 1